Pharmacy Times July 15, 2024
Consumer-wearable devices can monitor treatment response and provide continuous health data for patients with heart disease and atrial fibrillation.
Consumer wearable devices, which monitor heart rate and physical activity (PA) via a wristband connected smartphone, can provide clinically valuable data for comparing the efficacy of digoxin (Digox; Concordia Pharmaceuticals) versus beta-blockers in patients with atrial fibrillation (AF) and heart failure (HF), according to a study published in Nature Medicine. The findings support the potential of utilizing wearable technology and artificial intelligence (AI) to continuously monitor treatment responses, measure disease severity, and provide timely clinical information for patients with cardiovascular disease (CVD).
CVD is the leading cause of death in the US, accounting for approximately 928,741 deaths in 2020, and encompasses...
Today's Sponsors
Today's Sponsor